Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
REDWOOD CITY, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company focused on helping conquer cancer globally through use of its...
-
FDA grants breakthrough device designation to GuardantOMNI test usedfor plasma-based tumor mutational burden analysis in AstraZeneca trial Agreement covers immunotherapy and targeted therapy...
-
Revenue growth of 95% over prior year period REDWOOD CITY, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company focused on helping...
-
REDWOOD CITY, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter of 2018 after market close on...
-
REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH) today announced the closing of its initial public offering of 14,375,000 shares of common stock, which...
-
REDWOOD CITY, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH) today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public...